Federal News
Congress Seeks Transparency on Drug Pricing Deals
March 05, 2026
House and Senate Democratic health committee leaders, including Congressman Richard E. Neal and Senator Ron Wyden, have formally requested the Trump Administration to disclose secret most-favored-nation agreements with pharmaceutical companies related to Medicare drug pricing. They have raised concerns about the transparency and effectiveness of the Administration's GLOBE and GUARD Models designed to lower Medicare drug costs. This request highlights congressional oversight efforts aimed at ensuring accountability and clarity in pharmaceutical procurement and pricing strategies.
- Why this matters: Procurement professionals should anticipate potential policy shifts or increased scrutiny on drug pricing agreements that could impact contract terms and pricing transparency requirements.
- The focus on Medicare drug pricing models may lead to revised procurement guidelines or new compliance mandates for pharmaceutical vendors.
- Industry stakeholders should prepare for possible legislative or regulatory changes affecting pharmaceutical procurement processes and pricing disclosures.
- Agencies involved in healthcare procurement may need to adjust contracting strategies to align with evolving congressional expectations for transparency and cost-effectiveness.
Agencies
House Ways and Means Committee, House Energy and Commerce Committee, House Education and Workforce Committee, Senate Finance Committee, U.S. Department of Health and Human Services